Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.
Revive Announces Rights Offering to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria
Revive Therapeutics Provides Clinical and Corporate Update
Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2016
Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor
Revive Therapeutics Ltd Announces Results for the Three and Six Months Ended December 31, 2015